z-logo
Premium
Renal involvement of mantle cell lymphoma leading to end stage renal disease
Author(s) -
Lee Hyeon Jeong,
Seo Jong Woo,
Cho Hyun Seop,
Kang Yeojin,
Bae Eun Jin,
Lee Dong Won,
Jeon DaeHong,
Lee Jong Sil,
Chang SeHo,
Park Dong Jun
Publication year - 2012
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/j.1542-4758.2011.00612.x
Subject(s) - medicine , end stage renal disease , renal biopsy , hemodialysis , mantle cell lymphoma , chemotherapy , lymphoma , tumor lysis syndrome , gastroenterology , creatinine , surgery , kidney
Mantle cell lymphoma ( MCL ), owing to its insensitivity to chemotherapy, has a poor prognosis, with a median survival of 3 years to 4 years. MCL frequently infiltrates other organs. However, reports involving kidney in living patients are rare. Here, we report a case of MCL with renal involvement leading to end stage renal disease that required renal replacement therapy. A 69‐year‐old man diagnosed with MCL 3 years earlier was admitted to our emergency room due to uremic symptoms. After eight cycles of chemotherapy, he had displayed complete remission, but experienced a recurrence 1.5 years later; after refusing chemotherapy, the patient was lost on follow‐up in the final 10 months. On presentation at the emergency room, the patient's serum blood urea nitrogen was 109.5 mg/dL, and creatinine was 11.1 mg/dL. All serological markers for secondary glomerulonephritis were negative. Renal biopsy revealed 50% sclerosis of the glomerulus and small dense lymphocyte infiltration of the tubulo‐interstitium. Similar cells were found on the gastric mucosa. Despite our recommendation for chemotherapy, he refused all treatments except for hemodialysis, which was maintained for 12 months until his death. This patient represents the first case report of the renal involvement of MCL leading to end stage renal disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here